Johnson & Johnson: EPS up to $2.20 in Q1
(CercleFinance.com) - Sales grew by 2.
3% to $21.4bn in Q1 2024, with operating up 3.9% and adjusted operating increasing 4.0%. Excluding the COVID-19 vaccine, Q1 2024 EPS rose to $2.20 and adjusted EPS increased to $2.71, up 12.4%. Johnson & Johnson's strong first-quarter performance reflects its increased focus and progress in its portfolio and pipeline, it said. Our impact across the healthcare spectrum is unique in our industry, and the milestones achieved this quarter reinforce our position as an innovation powerhouse. For 2024, J&J says it is now targeting sales growth of 5.5% to 6%, with EPS expected between $10.60 and $10.75, taking into account the dilutive effect of the Laminar acquisition. Copyright (c) 2024 CercleFinance.com. All rights reserved. |
03/05/2024 17:36
Renaultpartenariat pluriannuel entre Alpine F1 et ApeCoin 03/05/2024 17:26 Novo Nordiskle titre recule, un analyste ajuste sa cible 03/05/2024 16:55 UMGtitre en hausse, un analyste relève sa cible 03/05/2024 16:00 ArkemaBlackRock sous les 5% du capital 03/05/2024 15:46 J&Jprésentera ses avancées dans les maladies de la rétine 03/05/2024 15:36 Nexansle titre recule, Barclays se veut prudent Tous les articles sociétés |
